Riaz A, Hieb H, Foley B, Mulvihill N, Crean P, Murphy R T, Daly C, Boyle N
Cardiology Department, St. James's Hospital, James St, Dublin 8.
Ir Med J. 2013 Feb;106(2):55-6.
Therapeutic hypothermia (TH) is a process of cooling a patient post ventricular tachycardia/ventricular fibrillation (VT/VF) cardiac arrest to 32-34 degrees C for 24 hours. This improves neurological outcome and is part of current guidelines. Hypothermia prolongs QT interval, which can precipitate torsades de pointes (TdP). We performed a retrospective review of all patients who received TH in our hospital over a period of 2 years to assess the effect of TH on the corrected OT interval (QTc) and any possible pro-arrhythmia. A total of 13 patients received TH. QTc prolonged in all patients with an average of 80.3 + 57.2 ms., and up to 109.8 + 80.4 ms in patients who received Amiodarone concurrently. No TdP was seen in any patient. We conclude that TH is safe, though careful monitoring of the OTc interval is advisable especially with concurrent use of QT prolonging drugs.
治疗性低温（TH）是指在室性心动过速/心室颤动（VT/VF）心脏骤停后将患者体温降至32 - 34摄氏度并持续24小时的过程。这可改善神经学预后，是当前指南的一部分。低温会延长QT间期，这可能引发尖端扭转型室性心动过速（TdP）。我们对我院2年内接受TH治疗的所有患者进行了回顾性研究，以评估TH对校正QT间期（QTc）的影响以及任何可能的促心律失常作用。共有13例患者接受了TH治疗。所有患者的QTc均延长，平均延长80.3 + 57.2毫秒，同时接受胺碘酮治疗的患者QTc延长高达109.8 + 80.4毫秒。所有患者均未出现TdP。我们得出结论，TH是安全的，不过建议密切监测QTc间期，尤其是在同时使用延长QT间期药物的情况下。
